Rosalind Walley

Pharmaco-metabonomic phenotyping and personalized drug treatment

T. Andrew Clayton, John C. Lindon, Olivier Cloarec et al. · Nature · 2006 · 823 citations

Drug Repositioning, Pharmacology, Pharmacotherapy +5

Minimizing Patient Burden Through the Use of Historical Subject-Level Data in Innovative Confirmatory Clinical Trials: Review of Methods and Opportunities

Jessica Lim, Rosalind Walley, Jiacheng Yuan et al. · Therapeutic Innovation & Regulatory Science · 2018 · 109 citations · Full text

Patient Selection, Historical Subject-level Data, Clinical Endpoint +19

First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus

Adina Tocoian, Peter Buchan, Hishani Kirby et al. · Lupus · 2015 · 71 citations

Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy

Wim H. Scheele, Susan M. Diamond, Jeremy D. Gale et al. · Journal of the American Society of Nephrology · 2016 · 64 citations · Full text

Advantages of a wholly Bayesian approach to assessing efficacy in early drug development: a case study

Rosalind Walley, Claire Smith, Jeremy D. Gale et al. · Pharmaceutical Statistics · 2015 · 56 citations

Bayesian Statistic, Bayesian Assurance, Evidence-based Medicine +19